Do analysts prefer RDY or NAMS?

NewAmsterdam Pharma has a consensus price target of $48.60, indicating a potential upside of 55.10%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 NewAmsterdam Pharma 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83

NewAmsterdam Pharma (NAMS) Competitors

$31.34 +0.52 (+1.67%)

As of 02:12 PM Eastern

Compare

NAMS vs. BBIO, AXSM, ELAN, RDY, and ARWR

Should you buy NewAmsterdam Pharma stock or one of its competitors? MarketBeat compares NewAmsterdam Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NewAmsterdam Pharma include BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry.

How does NewAmsterdam Pharma compare to BridgeBio Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

NewAmsterdam Pharma has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	162.80	-$203.82M	-$1.79	N/A
BridgeBio Pharma	$502.08M	26.96	-$724.93M	-$3.74	N/A

NewAmsterdam Pharma presently has a consensus price target of $48.60, indicating a potential upside of 55.10%. BridgeBio Pharma has a consensus price target of $91.05, indicating a potential upside of 31.73%. Given NewAmsterdam Pharma's higher possible upside, equities analysts plainly believe NewAmsterdam Pharma is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.84

BridgeBio Pharma has a net margin of -124.42% compared to NewAmsterdam Pharma's net margin of -943.23%. BridgeBio Pharma's return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
BridgeBio Pharma	-124.42%	N/A	-65.81%

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, BridgeBio Pharma had 12 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 12 mentions for BridgeBio Pharma and 0 mentions for NewAmsterdam Pharma. BridgeBio Pharma's average media sentiment score of 0.86 beat NewAmsterdam Pharma's score of 0.00 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
NewAmsterdam Pharma	Neutral
BridgeBio Pharma	Positive

NewAmsterdam Pharma has a beta of 0.07, indicating that its share price is 93% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

Summary

BridgeBio Pharma beats NewAmsterdam Pharma on 10 of the 17 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Axsome Therapeutics?

NewAmsterdam Pharma (NASDAQ:NAMS) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

NewAmsterdam Pharma presently has a consensus price target of $48.60, indicating a potential upside of 55.10%. Axsome Therapeutics has a consensus price target of $258.95, indicating a potential upside of 4.60%. Given NewAmsterdam Pharma's higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

In the previous week, Axsome Therapeutics had 9 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 9 mentions for Axsome Therapeutics and 0 mentions for NewAmsterdam Pharma. Axsome Therapeutics' average media sentiment score of 1.01 beat NewAmsterdam Pharma's score of 0.00 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
NewAmsterdam Pharma	Neutral
Axsome Therapeutics	Positive

Axsome Therapeutics has a net margin of -26.59% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

NewAmsterdam Pharma has a beta of 0.07, indicating that its stock price is 93% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

Axsome Therapeutics has higher revenue and earnings than NewAmsterdam Pharma. Axsome Therapeutics is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	162.80	-$203.82M	-$1.79	N/A
Axsome Therapeutics	$708.24M	17.99	-$183.17M	-$3.73	N/A

Summary

Axsome Therapeutics beats NewAmsterdam Pharma on 9 of the 16 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Elanco Animal Health has a net margin of -4.95% compared to NewAmsterdam Pharma's net margin of -943.23%. Elanco Animal Health's return on equity of 7.42% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

97.5% of Elanco Animal Health shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

NewAmsterdam Pharma has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.46	-$232M	-$0.50	N/A
NewAmsterdam Pharma	$22.50M	162.80	-$203.82M	-$1.79	N/A

Elanco Animal Health has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.07, suggesting that its stock price is 93% less volatile than the broader market.

Elanco Animal Health currently has a consensus price target of $28.55, suggesting a potential upside of 22.80%. NewAmsterdam Pharma has a consensus price target of $48.60, suggesting a potential upside of 55.10%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NewAmsterdam Pharma is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Elanco Animal Health had 7 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 7 mentions for Elanco Animal Health and 0 mentions for NewAmsterdam Pharma. Elanco Animal Health's average media sentiment score of 0.88 beat NewAmsterdam Pharma's score of 0.00 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Overall Sentiment
Elanco Animal Health	Positive
NewAmsterdam Pharma	Neutral

Summary

Elanco Animal Health beats NewAmsterdam Pharma on 10 of the 16 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Dr. Reddy's Laboratories has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.29	$456M	$0.58	24.35
NewAmsterdam Pharma	$22.50M	162.80	-$203.82M	-$1.79	N/A

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Dr. Reddy's Laboratories' average media sentiment score of 0.00 equaled NewAmsterdam Pharma'saverage media sentiment score.

Company	Overall Sentiment
Dr. Reddy's Laboratories	Neutral
NewAmsterdam Pharma	Neutral

Dr. Reddy's Laboratories has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to NewAmsterdam Pharma's net margin of -943.23%. Dr. Reddy's Laboratories' return on equity of 12.34% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

NewAmsterdam Pharma has a consensus price target of $48.60, indicating a potential upside of 55.10%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Dr. Reddy's Laboratories beats NewAmsterdam Pharma on 8 of the 15 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Arrowhead Pharmaceuticals?

NewAmsterdam Pharma (NASDAQ:NAMS) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

Arrowhead Pharmaceuticals has higher revenue and earnings than NewAmsterdam Pharma. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	162.80	-$203.82M	-$1.79	N/A
Arrowhead Pharmaceuticals	$829.45M	13.73	-$1.63M	-$2.15	N/A

In the previous week, Arrowhead Pharmaceuticals had 13 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 13 mentions for Arrowhead Pharmaceuticals and 0 mentions for NewAmsterdam Pharma. Arrowhead Pharmaceuticals' average media sentiment score of 1.12 beat NewAmsterdam Pharma's score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
NewAmsterdam Pharma	Neutral
Arrowhead Pharmaceuticals	Positive

NewAmsterdam Pharma has a beta of 0.07, suggesting that its stock price is 93% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

NewAmsterdam Pharma currently has a consensus price target of $48.60, indicating a potential upside of 55.10%. Arrowhead Pharmaceuticals has a consensus price target of $86.36, indicating a potential upside of 6.80%. Given NewAmsterdam Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe NewAmsterdam Pharma is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Arrowhead Pharmaceuticals has a net margin of -48.38% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Summary

NewAmsterdam Pharma beats Arrowhead Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get NewAmsterdam Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAMS vs. The Competition

Export

Metric	NewAmsterdam Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.66B	$2.98B	$6.49B	$12.17B
Dividend Yield	N/A	1.78%	2.68%	5.81%
P/E Ratio	-17.51	18.44	24.68	24.05
Price / Sales	162.80	343.78	530.15	111.08
Price / Cash	N/A	55.91	27.92	37.84
Price / Book	5.25	4.13	10.87	6.56
Net Income	-$203.82M	$64.45M	$3.56B	$336.88M
7 Day Performance	3.79%	3.04%	1.99%	0.06%
1 Month Performance	-11.58%	1.75%	0.74%	1.07%
1 Year Performance	72.08%	31.38%	33.47%	32.09%

NewAmsterdam Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAMS NewAmsterdam Pharma	2.0438 of 5 stars	$31.34 +1.7%	$48.60 +55.1%	+71.6%	$3.66B	$22.50M	N/A	4
BBIO BridgeBio Pharma	3.5002 of 5 stars	$66.64 -2.0%	$89.14 +33.8%	+65.2%	$13.05B	$502.08M	N/A	400
AXSM Axsome Therapeutics	2.3488 of 5 stars	$251.91 -0.6%	$256.79 +1.9%	+146.2%	$12.96B	$638.50M	N/A	380	Positive News
ELAN Elanco Animal Health	4.0135 of 5 stars	$24.23 -0.2%	$28.20 +16.4%	+77.6%	$12.10B	$4.72B	N/A	9,400
RDY Dr. Reddy's Laboratories	1.6332 of 5 stars	$13.31 -0.2%	N/A	-8.6%	$11.11B	$3.58B	22.94	27,527

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAMS) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NewAmsterdam Pharma (NAMS) Competitors

NAMS vs. BBIO, AXSM, ELAN, RDY, and ARWR

How does NewAmsterdam Pharma compare to BridgeBio Pharma?

Summary

How does NewAmsterdam Pharma compare to Axsome Therapeutics?

Summary

How does NewAmsterdam Pharma compare to Elanco Animal Health?

Summary

How does NewAmsterdam Pharma compare to Dr. Reddy's Laboratories?

Summary

How does NewAmsterdam Pharma compare to Arrowhead Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS vs. The Competition

NewAmsterdam Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NewAmsterdam Pharma (NAMS) Competitors

NAMS vs. BBIO, AXSM, ELAN, RDY, and ARWR

How does NewAmsterdam Pharma compare to BridgeBio Pharma?

Which has stronger valuation & earnings, NAMS or BBIO?

Do analysts prefer NAMS or BBIO?

Is NAMS or BBIO more profitable?

Do insiders and institutionals have more ownership in NAMS or BBIO?

Does the media prefer NAMS or BBIO?

Which has more risk & volatility, NAMS or BBIO?

Summary

How does NewAmsterdam Pharma compare to Axsome Therapeutics?

Do analysts prefer NAMS or AXSM?

Does the media refer more to NAMS or AXSM?

Is NAMS or AXSM more profitable?

Do insiders and institutionals believe in NAMS or AXSM?

Which has more risk & volatility, NAMS or AXSM?

Which has better earnings and valuation, NAMS or AXSM?

Summary

How does NewAmsterdam Pharma compare to Elanco Animal Health?

Is ELAN or NAMS more profitable?

Do institutionals & insiders hold more shares of ELAN or NAMS?

Which has better earnings & valuation, ELAN or NAMS?

Which has more volatility & risk, ELAN or NAMS?

Do analysts rate ELAN or NAMS?

Does the media prefer ELAN or NAMS?

Summary

How does NewAmsterdam Pharma compare to Dr. Reddy's Laboratories?

Which has higher earnings and valuation, RDY or NAMS?

Do insiders & institutionals believe in RDY or NAMS?

Does the media prefer RDY or NAMS?

Which has more volatility and risk, RDY or NAMS?

Is RDY or NAMS more profitable?

Do analysts prefer RDY or NAMS?

Summary

How does NewAmsterdam Pharma compare to Arrowhead Pharmaceuticals?

Which has stronger valuation and earnings, NAMS or ARWR?

Does the media favor NAMS or ARWR?

Which has more volatility & risk, NAMS or ARWR?

Do analysts prefer NAMS or ARWR?

Do insiders and institutionals believe in NAMS or ARWR?

Is NAMS or ARWR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS vs. The Competition

NewAmsterdam Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools